Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

Author： Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.38, Iss.1, 2010-01, pp. : 9-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite

An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

By Scagliotti Giorgio  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2855-2866

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review

By Bongers Mathilda L.  

PharmacoEconomics, Vol. 30, Iss. 1, 2012-01 ,pp. : 17-34

Adis International

Access to resources Recommend Favorite

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

By  

Current Clinical Pharmacology, Vol. 13, Iss. 2, 2018-05 ,pp. : 76-84

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 58-60

Bentham Science Publishers

Access to resources Recommend Favorite